Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Clinical Germline Testing Evaluated for Pediatric Cancer Patients

By LabMedica International staff writers
Posted on 04 Mar 2021
Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have found heritable germline predisposition in 8%–12% of patients.

The yield of germline predisposition detected is dependent on the genes included for analysis and variant interpretation as well as the ascertainment biases found in each cohort. Iterative data are required to expand upon the understanding of susceptibility to pediatric cancer and determine the extent to which germline data may translate into clinical practice.

Pediatricians and their colleagues at Memorial Sloan Kettering Cancer Center (New York, NY, USA) conducted matched tumor-normal DNA sequencing on 751 pediatric cancer patients treated at the center from July 2015 to July 2020. Tumor and blood samples were obtained and sequenced using the MSK-IMPACT platform, a capture-based NGS assay capable of identifying sequence mutations, copy number alterations and select gene fusions in 468 genes. Germline data were analyzed in 88 genes and germline pathogenic and likely pathogenic (P/LP) variants were reported. The study covered several different cancer types, including sarcoma, neuroblastoma, central nervous system (CNS) tumors, retinoblastoma, and other rare solid tumors.

The team reported that one or more P/LP variants were found in 138/751 (18%) of individuals when including variants in low-, moderate- and high-penetrance dominant or recessive genes or in 99/751 (13%) of individuals in moderate- and high-penetrance dominant genes. The found 34% of high- or moderate-penetrance variants were unexpected based on the patient’s diagnosis and previous history and 76% of patients with positive results completed a clinical genetics visit, and 21% had at least one relative undergo cascade testing as a result of this testing.

Germline variants were found in 49% of patients with retinoblastoma, 21% of patients with CNS tumors, 15% of patients with neuroblastoma, 12% of patients with sarcoma, and 19% of patients with other tumor types. The most common mutations in high- or moderate-penetrance genes were in RB1 (found in 4% of patients), NF1 (1%) and TP53 (1%) in patients with retinoblastoma and those with a prior clinical diagnoses of neurofibromatosis type 1 (NF1) - or Li Fraumeni syndrome (LFS)-associated tumors.

About 3% of patients had variants in DNA damage repair genes, 1.6 % had mutations in the RAS–MEK or mTOR–PTEN pathway, and 1% had variants in metabolic pathways related to cancer. Among genetic diseases that were not identified by MSK-IMPACT in this study was the growth disorder Beckwith–Wiedemann syndrome, identified in four patients. The authors suggested combining multiple tests in such cases, like next-generation sequencing (NGS) and RNA sequencing, to detect all types of genetic variants.

The authors noted that potential cost savings exist through cancer screening and early detection, prevention, pre-implantation genetic testing, and potentially more effective therapeutics; however, there are also significant costs associated with each of these in addition to the costs of sequencing and clinical genetics visits. The study was published on February 15, 2021 in the journal Nature Cancer.

Related Links:
Memorial Sloan Kettering Cancer Center


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Troponin I Test
Quidel Triage Troponin I Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.